CDXC: ChromaDex Corporation Stock

by  •  • Comments Off on CDXC: ChromaDex Corporation Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 584.08
Enterprise Value ($M) 551.83
Book Value ($M) 34.37
Book Value / Share 0.45
Price / Book 16.99
NCAV ($M) 29.98
NCAV / Share 0.39
Price / NCAV 19.48

Profitability (mra)
Return on Invested Capital (ROIC) 0.04
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.05

Liquidity (mrq)
Quick Ratio 2.35
Current Ratio 2.95

Balance Sheet (mrq) ($M)
Current Assets 52.13
Assets 56.52
Liabilities 22.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-21 13D/A Prime Tech Global Ltd 0.00
08-21 13D/A Pioneer Step Holdings Ltd 25.41 144.68

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-3775
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 152,904 1,021,474 14.97
2024-11-21 235,006 968,161 24.27
2024-11-20 114,338 545,191 20.97
2024-11-19 271,453 1,104,250 24.58
2024-11-18 239,230 1,382,731 17.30

(click for more detail)

Similar Companies
CDIO – Cardio Diagnostics Holdings, Inc. CDMO – Avid Bioservices, Inc.
CDTX – Cidara Therapeutics, Inc. CELU – Celularity Inc.
CELZ – Creative Medical Technology Holdings, Inc.


Financial data and stock pages provided by
Fintel.io